K

Kaken Pharmaceutical Co Ltd
TSE:4521

Watchlist Manager
Kaken Pharmaceutical Co Ltd
TSE:4521
Watchlist
Price: 4 222 JPY -0.82% Market Closed
Market Cap: 159.9B JPY
Have any thoughts about
Kaken Pharmaceutical Co Ltd?
Write Note

Kaken Pharmaceutical Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kaken Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
K
Kaken Pharmaceutical Co Ltd
TSE:4521
Cash from Operating Activities
ÂĄ26.8B
CAGR 3-Years
27%
CAGR 5-Years
-2%
CAGR 10-Years
10%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash from Operating Activities
ÂĄ876.3B
CAGR 3-Years
-5%
CAGR 5-Years
10%
CAGR 10-Years
14%
Daiichi Sankyo Co Ltd
TSE:4568
Cash from Operating Activities
ÂĄ583.9B
CAGR 3-Years
73%
CAGR 5-Years
25%
CAGR 10-Years
17%
Otsuka Holdings Co Ltd
TSE:4578
Cash from Operating Activities
ÂĄ379.8B
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
8%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash from Operating Activities
ÂĄ409.9B
CAGR 3-Years
17%
CAGR 5-Years
21%
CAGR 10-Years
27%
Astellas Pharma Inc
TSE:4503
Cash from Operating Activities
ÂĄ200.8B
CAGR 3-Years
-15%
CAGR 5-Years
-4%
CAGR 10-Years
-1%
No Stocks Found

Kaken Pharmaceutical Co Ltd
Glance View

Market Cap
159.9B JPY
Industry
Pharmaceuticals

Founded in 1948, Kaken Pharmaceutical Co., Ltd. is a prominent player in Japan's pharmaceutical landscape, seamlessly blending tradition with innovation. The company's journey began amidst post-war economic rebuilding, initially catering to the nation's healthcare needs with basic medicines. Over the years, it has carved out a niche for itself, specializing in the development, manufacturing, and commercialization of a wide range of pharmaceutical products. Kaken's focus areas include dermatology, orthopedics, and surgery, with a strong emphasis on treatments for fungal infections and inflammation management. This specialization has propelled the company into a position of leadership, especially in the dermatology market, where its expertise in topical formulations excels. Kaken Pharmaceutical monetizes its ventures primarily through the sale of prescription and over-the-counter drugs, leveraging a robust distribution network that extends its reach across Japan and international markets. The company continually reinvests in research and development to sustain its competitive edge, regularly introducing innovative therapies that address unmet medical needs. While pharmaceuticals remain its core revenue stream, Kaken also generates income from its chemical businesses, which include agrochemicals and animal health products, further diversifying its portfolio. By maintaining a balanced blend of traditional pharmaceutical sales and chemical product lines, Kaken ensures steady financial footing while advancing health solutions for a global audience.

Intrinsic Value
1 867.16 JPY
Overvaluation 56%
Intrinsic Value
Price
K

See Also

What is Kaken Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
26.8B JPY

Based on the financial report for Sep 30, 2024, Kaken Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 26.8B JPY.

What is Kaken Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%

Over the last year, the Cash from Operating Activities growth was 936%. The average annual Cash from Operating Activities growth rates for Kaken Pharmaceutical Co Ltd have been 27% over the past three years , -2% over the past five years , and 10% over the past ten years .

Back to Top